随着健康焦虑成为消费重要驱动力，矫姿带市场热度持续攀升，背背佳凭借明星代言与网红营销再度走 红，一条售价499元毛利率超60%。 近期背背佳母公司可孚医疗科技股份有限公司计划赴港IPO，试图以"全生命周期健康管理"叙事支撑估 值，但行业发展面临产品同质化严重、监管盲区、产品效果分歧等挑战。 康复辅具超60%的毛利率背后，是"暴利"还是"高价值"？ 可孚医疗2025年上半年财报显示，矫姿带所在的康复辅助类产品毛利率高达61.99%，远超公司其他产 品线38%—48%的毛利率区间，其创造的3.489亿元毛利占据公司总毛利的44.44%，撑起近半利润成为推 动公司盈利的核心力量。 据了解其背背佳及相关矫姿带产品核心技术主要集中在力学设计和材料选择上，专利多为外观专利和实 用新型专利而非技术含量更高的发明专利，对创新性和技术难度要求较低，生产过程类似普通服装制 造，如裁剪、缝制、组装等环节工艺简单、成本可控。 成本主要集中在营销和渠道上，利用消费者对体态的焦虑心理精准定位目标人群，比如早期针对青少年 市场，宣传"矫正坐姿"以迎合家长对孩子成长的担忧，后来转向成年人市场，强调"身材管理""改善体 态"等功能满足职场人群 ...

证券之星消息，截至2025年12月11日收盘，可孚医疗(301087)报收于45.47元，下跌1.2%，换手率 2.2%，成交量4.27万手，成交额1.96亿元。 12月11日的资金流向数据方面，主力资金净流出1740.11万元，占总成交额8.87%，游资资金净流入 851.25万元，占总成交额4.34%，散户资金净流入888.86万元，占总成交额4.53%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-11 | 45.47 | -1.20% | -1740.11万 | -8.87% | 851.25万 | 4.34% | 888.86万 | - 4.53% | | 2025-12-10 | 46.02 | 4.14% | -5083.32万 | -13.91% | 1989.34万 | 5.44% | 3093.98万 | 8.47% | | 2025-12-09 | | ...

Group 1: Food and Beverage Industry - The report emphasizes prioritizing growth while focusing on undervalued traditional consumer leaders with strong long-term growth certainty, particularly in the soft drink sector, where companies like Nongfu Spring and Dongpeng Beverage show increased valuation attractiveness [1][4] - Recommendations include growth-oriented and stable targets in the liquor sector, such as Shanxi Fenjiu and Guizhou Moutai, alongside structural high-growth beverage companies like Dongpeng Beverage and Nongfu Spring [2] - The snack and food raw material sectors are highlighted for growth opportunities, with companies like Bailing Chuangyuan and Three Squirrels recommended for investment [2] Group 2: Strategy and Market Trends - The AI industry continues to show high prosperity, with demand for high-end storage devices like DRAM DDR4 increasing, driven by ongoing AI infrastructure investments [5][7] - Service consumption has seen a significant year-on-year increase, with notable improvements in tourism and entertainment sectors, indicating a shift towards light consumption types [6] - The real estate and durable goods sectors are experiencing a marginal decline in prosperity, with industrial metal prices rising significantly due to global supply dynamics [5][6] Group 3: Biopharmaceuticals - The report maintains a "Buy" rating for Kefu Medical, highlighting a strong revenue growth of 30.72% in Q3 2025, with a focus on improving operational efficiency in its hearing aid business [9][10]

Core Points - The Chinese government will ban the production of mercury thermometers and blood pressure monitors starting January 1, 2026, in compliance with the Minamata Convention on Mercury [1][3] - The ban is driven by the toxic nature of mercury and its environmental hazards, with a standard mercury thermometer containing about 1 to 2 grams of mercury, which can significantly exceed safe concentration levels if broken [1][3] - Following the announcement, there has been a surge in demand for mercury thermometers on e-commerce platforms, leading to stock shortages due to their low price compared to electronic alternatives [1][8] Policy Background - The ban is part of China's commitment to the Minamata Convention, which took effect in China on August 16, 2017, and was further detailed by the National Medical Products Administration in October 2020 [3] - The environmental and health risks associated with mercury, including irreversible damage to the nervous system and kidneys, particularly in vulnerable populations like children and pregnant women, are key considerations for the ban [3] Market Reaction - E-commerce platforms like JD.com and Taobao have reported limited stock and shortages of mercury thermometers following the announcement of the ban [3] - The price of mercury thermometers is generally under 10 yuan, while electronic thermometers range from tens to hundreds of yuan, creating a significant price difference that drives consumer behavior [8] Company Responses - Companies such as Yuyue Medical (002223), Jiuan Medical (002432), and Kefu Medical (301087) have indicated that the impact of the ban on their businesses will be limited, as the share of mercury products in their portfolios is small [9][10] - Yuyue Medical, once a leader in the mercury blood pressure monitor market with an 85% market share, has transitioned to electronic products and reported a revenue of 7.972 billion yuan in 2023 [9] - Jiuan Medical stated that it is not a traditional thermometer manufacturer and has minimal exposure to mercury products, suggesting that the exit of mercury products may create opportunities in the electronic thermometer market [10] Industry Outlook - The global blood pressure monitor market is projected to grow from 2.15 billion USD in 2025 to 3.97 billion USD by 2032, with a compound annual growth rate of 9.2% [10] - The market for electronic thermometers and infrared measuring devices is expected to expand as consumer preferences shift away from mercury products [10][12] - Major players in the electronic blood pressure monitor market include Omron and Yuyue, with domestic brands like Jiuan and Kefu gaining market share through e-commerce strategies [12]

Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) experienced a slight decline of 0.41%, closing at 4415.21 points on December 10, with a trading volume of 6.972 billion yuan and a turnover rate of 0.9% [1] Group 1: Index Performance - The Shenzhen-Hong Kong Medical Index closed at 4415.21 points, down 0.41% [1] - The index had a trading volume of 6.972 billion yuan and a turnover rate of 0.9% [1] - Among the constituent stocks, 21 companies saw an increase, with Kewei Medical leading at a 4.14% rise, while 36 companies declined, with Xianjian Technology leading the drop at 9.14% [1] Group 2: Capital Flow - The net outflow of main funds from the Shenzhen-Hong Kong Medical Index constituent stocks totaled 382 million yuan [2] - Retail investors contributed a net inflow of 329 million yuan, while speculative funds saw a net inflow of 53.373 million yuan [2] - Detailed capital flow information for the constituent stocks is available in the accompanying table [2]

Core Insights - Kefu Medical, a leading Chinese home medical device company, has signed a strategic cooperation agreement with Royal Philips to enhance the availability of high-quality health technology products in Chinese households [1][3]. Group 1: Company Overview - Kefu Medical has over 20 years of experience in the industry and has established a comprehensive system covering research and development, production, distribution, e-commerce, and logistics [3]. - The company exports its products to over 60 countries and regions globally and holds a significant position in both online and offline markets in China [3]. Group 2: Strategic Partnership - The agreement allows Kefu Medical to obtain brand authorization for multiple home health monitoring devices from Royal Philips, including blood glucose meters, blood pressure monitors, continuous glucose monitoring devices (CGM), thermometers, pulse oximeters, pulmonary function meters, and scales [3]. - The partnership aims to create smart health management solutions tailored to the needs of Chinese families, promoting a new era of precision, intelligence, and contextualization in the domestic health monitoring sector [3]. Group 3: Product Development and Market Strategy - The first batch of Royal Philips smart monitoring medical devices is in the preparation stage for market launch, focusing on innovative and forward-looking product solutions for consumers [4]. - Future products will leverage enhanced online channel strategies to solidify market leadership, utilizing Kefu Medical's retail system, national and regional distribution networks, major chain pharmacies, specialized medical device stores, and clinics for rapid business expansion and coverage [4].

Group 1: Strategic Partnerships - Royal Philips has granted Kefu Medical brand authorization for various home health monitoring devices in Greater China, including blood glucose meters, blood pressure monitors, thermometers, and pulse oximeters, following a comprehensive evaluation of the company's capabilities [2] - The collaboration aims to deepen R&D synergy and localization, integrating international branding with leading Chinese technology and industrial capabilities [2] Group 2: Overseas Business Growth - Kefu Medical has made significant progress in its global strategy, achieving high growth in overseas business due to accumulated customer resources and enhanced customer loyalty [2] - B2B order amounts are steadily increasing, supported by successful integration of acquisitions such as Huazhou and Ximan, which are releasing synergistic effects for sustained international business growth [2] Group 3: Product Development in Respiratory Sector - The respiratory machine segment focuses on user needs, with plans to launch three new respiratory machines and masks in 2026, incorporating AI algorithms for real-time sleep analysis and advanced noise reduction technology [3] - Kefu's respiratory machines have seen rapid sales growth since launch, achieving leading performance in both product capabilities and online sales channels, driving revenue growth for the second half of the year and beyond [3] Group 4: Future Development Plans - Over the next 3-5 years, Kefu Medical will focus on independent innovation and global expansion, while deepening strategic cooperation with Royal Philips to promote high-quality development [4] - The company plans to increase R&D investment in core categories such as respiratory health, hearing assistance, rehabilitation care, and home testing, aiming for product intelligence upgrades and the establishment of a proprietary technology platform [4] - Kefu Medical will enhance its overseas localization capabilities and steadily expand its international market presence through a combination of organic growth and acquisition strategies [4]

Core Viewpoint - The strategic partnership between Kefu Medical and Royal Philips aims to enhance the availability of high-quality health technology products in Chinese households through collaboration on various home health monitoring devices [1][4]. Group 1: Partnership Details - Kefu Medical has obtained brand authorization from Royal Philips for multiple home health monitoring devices in China, including blood glucose meters, blood pressure monitors, continuous glucose monitoring devices (CGM), thermometers, pulse oximeters, pulmonary function instruments, and weighing scales [1]. - The collaboration will focus on joint technology research and development, local adaptation, and iterative upgrades, with Kefu Medical responsible for production, brand operation, channel layout, and service system construction in China [1][4]. Group 2: Strengths of the Companies - The partnership represents a deep synergy between an internationally recognized brand and a leading domestic enterprise, combining Philips' century-long technological expertise and global brand resources with Kefu Medical's strengths in innovation, smart manufacturing, and channel operations [4]. - Philips is a global leader in health technology, committed to enhancing health and well-being through innovation, while Kefu Medical is one of China's largest home medical device companies, with over 20 years of industry experience and a comprehensive supply chain covering R&D, production, distribution, e-commerce, and logistics [4]. Group 3: Market Context and Future Outlook - The collaboration aligns with China's national strategy to promote health, transitioning from a disease-centered approach to a health-centered one, as the demand for daily monitoring of blood pressure, blood glucose, blood oxygen, and temperature continues to grow [5]. - Analysts believe that this partnership will set new industry standards in technology, product innovation, and service quality, facilitating the faster and broader introduction of advanced medical devices into Chinese households [5]. - The first batch of Philips smart monitoring medical devices is in the preparation stage for market launch, with plans to enhance online channel layouts and leverage various distribution networks for rapid business expansion and coverage [5].

Core Viewpoint - The strategic partnership between Kewei Medical and Royal Philips aims to enhance the availability of high-quality health technology products in Chinese households through collaboration on various home health monitoring devices [1] Group 1: Partnership Details - Kewei Medical has signed a strategic cooperation agreement with Royal Philips to collaborate on multiple home health monitoring devices [1] - The agreement grants Kewei Medical brand authorization for several Philips health monitoring devices in China, including blood glucose meters, blood pressure monitors, continuous glucose monitoring devices, thermometers, pulse oximeters, pulmonary function meters, and weighing scales [1] Group 2: Product Development and Market Strategy - Both companies will work together on technology research and development, local adaptation, and iterative upgrades of the products [1] - Kewei Medical will be responsible for production, brand operation, channel layout, and service system construction in China, aiming for deep integration of research and innovation with industrial capabilities [1] Group 3: Market Expansion Plans - The first batch of Philips smart monitoring medical devices is in the preparation stage for market launch, focusing on innovative and forward-looking product solutions for consumers [1] - Future strategies include strengthening online channel layouts to consolidate market leadership and leveraging a diverse distribution network, including retail systems, national and regional distributors, major chain pharmacies, specialized medical device stores, and clinics for rapid business expansion [1]

Industry Overview - The National Medical Products Administration of China will ban the production of mercury thermometers and sphygmomanometers starting January 1, 2026, marking the end of mercury-based medical devices [1] - Electronic thermometers and blood pressure monitors have become mainstream alternatives, with a significant market opportunity as the penetration rate of home electronic blood pressure monitors in China is only 5%-10%, compared to over 50% in the US and Japan [1] - Advances in sensor technology, big data analytics, and artificial intelligence are expected to enhance the measurement accuracy and smart features of electronic thermometers [1] - AI algorithms in electronic thermometers can predict the likelihood of fever, improving user experience [1] - Next-generation electronic blood pressure monitors, especially those using the Korotkoff sound method with AI capabilities, are anticipated to effectively replace mercury sphygmomanometers in both clinical and home settings [1] Company Insights - Leshi Medical holds approximately 9.2% market share in the electronic thermometer market in 2023, ranking third in the industry, with a focus on "health management" through smart wearable thermometers integrated with mobile apps [2] - Kefu Medical is continuously expanding its product range and improving quality and technology, offering high-quality best-selling products including electronic blood pressure monitors, nursing beds, infrared thermometers, hearing aids, and nebulizers [2]